DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT (DRRX), a late-stage biopharmaceutical company focused on epigenetic therapies for acute organ injury and cancer, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York City.
Key points:
- DURECT management will be present at the conference
- Virtual 1x1 meetings will be available during the conference dates
- Attendees can request meetings through H.C. Wainwright
This participation provides an opportunity for DURECT to showcase its innovative approach in developing treatments for serious and life-threatening conditions to potential investors and industry professionals.
DURECT (DRRX), un'azienda biofarmaceutica in fase avanzata focalizzata sulle terapie epigenetiche per lesioni acute degli organi e il cancro, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale di Investimento H.C. Wainwright. L'evento è previsto per 9-11 settembre 2024 a New York City.
Punti chiave:
- Il management di DURECT sarà presente alla conferenza
- Incontri virtuali 1x1 saranno disponibili durante le date della conferenza
- I partecipanti possono richiedere incontri tramite H.C. Wainwright
Questa partecipazione offre a DURECT l'opportunità di mostrare il suo approccio innovativo nello sviluppo di trattamenti per condizioni gravi e potenzialmente letali a investitori e professionisti del settore.
DURECT (DRRX), una empresa biofarmacéutica en etapa avanzada centrada en terapias epigenéticas para lesiones agudas de órganos y cáncer, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento está programado para 9-11 de septiembre de 2024 en la ciudad de Nueva York.
Puntos clave:
- La dirección de DURECT estará presente en la conferencia
- Se ofrecerán reuniones virtuales 1x1 durante las fechas de la conferencia
- Los asistentes pueden solicitar reuniones a través de H.C. Wainwright
Esta participación brinda a DURECT la oportunidad de presentar su enfoque innovador en el desarrollo de tratamientos para afecciones graves y potencialmente mortales a inversores y profesionales de la industria.
DURECT (DRRX), 급성 장기 손상 및 암에 대한 후생유전학 치료에 집중하는 말기 바이오 제약 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참가한다고 발표했습니다. 이 이벤트는 2024년 9월 9일부터 11일까지 뉴욕시에서 예정되어 있습니다.
주요 사항:
- DURECT 경영진이 회의에 참석합니다
- 회의 기간 동안 가상 1:1 미팅이 가능합니다
- 참가자는 H.C. Wainwright를 통해 미팅을 요청할 수 있습니다
이번 참여는 DURECT가 중대한 생명 위협 조건에 대한 치료법을 개발하는 혁신적인 접근 방식을 잠재적 투자자와 업계 전문가들에게 선보일 수 있는 기회를 제공합니다.
DURECT (DRRX), une entreprise biopharmaceutique en phase avancée axée sur les thérapies épigénétiques pour les lésions aiguës des organes et le cancer, a annoncé sa participation à la 26e Conférence Annuelle Globale d'Investissement H.C. Wainwright. L'événement est prévu pour 9-11 septembre 2024 à New York.
Points clés :
- La direction de DURECT sera présente à la conférence
- Des réunions virtuelles 1x1 seront disponibles pendant les dates de la conférence
- Les participants peuvent demander des réunions via H.C. Wainwright
Cette participation offre à DURECT l'occasion de présenter son approche innovante dans le développement de traitements pour des conditions graves et potentiellement mortelles à des investisseurs et des professionnels de l'industrie.
DURECT (DRRX), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf epigenetische Therapien für akute Organschäden und Krebs konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekanntgegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York City statt.
Wichtige Punkte:
- Die Geschäftsführung von DURECT wird an der Konferenz teilnehmen
- Virtuelle 1x1-Meetings werden während der Konferenztermine verfügbar sein
- Teilnehmer können über H.C. Wainwright Meetings anfordern
Diese Teilnahme bietet DURECT die Möglichkeit, seinen innovativen Ansatz zur Entwicklung von Behandlungen für schwerwiegende und lebensbedrohliche Erkrankungen potenziellen Investoren und Branchenprofis zu präsentieren.
- None.
- None.
Management will also be available for virtual 1×1 meetings from September 9-11, 2024 during the conference. If attendees would like to request a meeting, please contact H.C. Wainwright directly.
About DURECT Corporation
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted Fast Track and Breakthrough Therapy designation; metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the
DURECT Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the potential to develop larsucosterol for AH, MASH or other indications, and the potential uses and benefits, if any, of our product candidates. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risks that the Company is unable to raise sufficient capital to commence the Phase 3 trial of larsucosterol in AH, trial enrollment or completion takes longer than anticipated, future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, and that larsucosterol may never be approved; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our need or desire for additional financing, our ability to continue to meet the minimum bid price for continued listing on Nasdaq, our ability to obtain capital to fund our operations and expenses, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission (SEC) filings, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024 under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-hc-wainwright-global-investment-conference-302238471.html
SOURCE DURECT Corporation
FAQ
When is DURECT (DRRX) presenting at the H.C. Wainwright Global Investment Conference?
What type of meetings will DURECT (DRRX) be available for during the conference?
How can attendees request a meeting with DURECT (DRRX) at the H.C. Wainwright conference?
What is the focus of DURECT 's (DRRX) research and development?
